Mira pharmaceuticals inc MIRA.US Overview Analysis

MIRA AI Analysis Overview

MIRA Current Performance

Top 10 High Relevance to MIRA

• PVLA Palvella therapeutics inc

  Value 2Trend 2Swing Trading 4Whale Interest 2Dividend 1

  See more
• WINT Windtree therapeutics inc
• TKNO Alpha teknova inc
• BMY Bristol-myers squibb company
• RGC Regencell bioscience holdings ltd
• SGMO Sangamo therapeutics inc
• SLRX Salarius pharmaceuticals inc
• DVAX Dynavax technologies corporation
• KNSA Kiniksa pharmaceuticals international plc
• MEIP Mei pharma incorporation

MIRA Profile

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial. It is for patients suffering from neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD). MIRA-55 is a preclinical-stage investigational drug designed to support cognitive function and enhance memory. It is for the treatment of patients experiencing cognitive decline, including those with early neurodegenerative conditions.